Literature DB >> 21389995

Biosimilars encircle Rituxan, US debates innovator exclusivity.

Karen Carey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389995     DOI: 10.1038/nbt0311-177

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Pharma swept up in biogenerics gold rush.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

  1 in total
  4 in total

1.  Biosimilars: the debate continues.

Authors:  Robert A Colbert; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2011-10

2.  Rituximab and biosimilars - equivalence and reciprocity.

Authors:  Zaina P Qureshi; Jametta S Magwood; Sarveshwari Singh; Charles L Bennett
Journal:  Biosimilars       Date:  2013-06-14

Review 3.  Expert perspectives on biosimilar monoclonal antibodies in breast cancer.

Authors:  J Cortés; G Curigliano; V Diéras
Journal:  Breast Cancer Res Treat       Date:  2014-02-23       Impact factor: 4.872

4.  Antibody therapy of pediatric B-cell lymphoma.

Authors:  Friederike Meyer-Wentrup; Verena de Zwart; Marc Bierings
Journal:  Front Oncol       Date:  2013-04-02       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.